
Abner Antonio Murray/Bluesky
Apr 30, 2025, 05:41
Abner Antonio Murray: Zongertinib delivers major hope for pretreated HER2-mutant NSCLC
Abner Antonio Murray, Hematology-Oncology Fellow at UNC Hematology-Oncology Fellowship, shared a post on X:
“Breaking at AACR25:
Zongertinib delivers major hope for pretreated HER2-mutant NSCLC.
71% ORR and 96% DCR in patients with TKD HER2 mutations (Cohort 1)
Median PFS 12.4 months; DoR 14.1 months durable benefit
Manageable safety: low ≥G3 AEs, no drug-related ILD
48% ORR even after HER2-directed ADC resistance (T-DXd)
Clinical benefit seen even in patients with brain metastases
FDA Priority Review underway for advanced/metastatic HER2+ NSCLC
Beamon LUNG-2 Phase 3 trial enrolling for 1L therapy
Zongertinib could redefine treatment for this high-need population.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 30, 2025, 04:15
Apr 30, 2025, 04:09
Apr 30, 2025, 03:47
Apr 30, 2025, 03:33
Apr 30, 2025, 00:18